Cogent Biosciences, Inc.
US ˙ NasdaqGS ˙ US19240Q2012

Introduction

This page provides a comprehensive analysis of the known insider trading history of Matthew Ros. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Matthew Ros has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:VSTM / Verastem, Inc. Chief Operating Officer 50,000
US:COGT / Cogent Biosciences, Inc. Director 2,650
US:EPZM / Epizyme Inc See Remarks 134,178
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Matthew Ros. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases COGT / Cogent Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in COGT / Cogent Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COGT / Cogent Biosciences, Inc. Insider Trades
Insider Sales COGT / Cogent Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in COGT / Cogent Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COGT / Cogent Biosciences, Inc. Insider Trades
Insider Purchases VSTM / Verastem, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in COGT / Cogent Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSTM / Verastem, Inc. Insider Trades
Insider Sales VSTM / Verastem, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in COGT / Cogent Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSTM / Verastem, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Matthew Ros as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-04-03 2025-04-01 4 VSTM Verastem, Inc.
Common Stock
A - Award 50,000 50,000
2022-04-05 2022-04-01 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 2,650 2,650 4.86 12,879 12,879
2022-01-04 2022-01-03 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 2,256 2,256 5.15 11,625 11,625
2021-10-05 2021-10-01 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 2,463 2,463 5.03 12,393 12,393
2021-08-18 2021-08-16 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 134,178 134,178
2021-08-18 2021-08-16 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 28,125 111,313 33.81
2021-07-06 2021-07-01 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 2,225 2,225 4.78 10,625 10,625
2021-04-05 2021-04-01 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 2,068 2,068 5.66 11,696 11,696
2021-03-15 2021-03-11 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 60,000 60,000
2021-02-05 2021-02-04 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -894 83,188 -1.06 11.21 -10,022 932,537
2021-02-02 2021-02-01 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 134,178 134,178
2021-02-02 2021-02-01 4 EPZM Epizyme, Inc.
Common Stock
A - Award 28,125 84,082 50.26
2021-01-27 2021-01-25 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -2,872 55,957 -4.88 11.41 -32,770 638,469
2021-01-06 2021-01-04 4 COGT Cogent Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 1,641 1,641
2020-10-02 2020-10-01 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 9,247 9,247 1.35 12,500 12,500
2020-07-06 2020-07-01 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 35,280 35,280 0.31 11,000 11,000
2020-06-30 2020-06-26 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -2,728 57,507 -4.53 16.15 -44,057 928,738
2020-06-30 2020-06-25 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 6,000 60,235 11.06
2020-06-30 2020-03-24 4/A EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 4,000 54,235 7.96
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
M - Exercise X -68,651 104,787 -39.58
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
M - Exercise X -2,289 107,577 -2.08
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
M - Exercise X -41,063 110,557 -27.08
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -68,651 51,798 -57.00 21.65 -1,486,294 1,121,427
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
M - Exercise X 68,651 120,449 132.54 9.58 657,677 1,153,901
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -2,289 51,798 -4.23 22.00 -50,358 1,139,556
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
M - Exercise X 2,289 54,087 4.42 12.45 28,498 673,383
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -41,063 51,798 -44.22 20.50 -841,792 1,061,859
2020-06-22 2020-06-18 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
M - Exercise X 41,063 92,861 79.28 9.12 374,495 846,892
2020-06-11 2020-06-09 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 14,331 14,331
2020-04-08 2020-04-06 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 49,887 49,887 0.22 11,000 11,000
2020-03-26 2020-03-25 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -1,243 51,798 -2.34 15.28 -18,993 791,473
2020-03-26 2020-03-24 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 1,563 53,041 3.04
2020-02-05 2020-02-03 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 56,213 56,213
2020-02-05 2020-02-03 4 EPZM Epizyme, Inc.
Common Stock
A - Award 11,688 51,478 29.37
2020-01-27 2020-01-24 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
F - Taxes -2,395 39,790 -5.68 22.40 -53,648 891,296
2020-01-27 2020-01-24 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -1,847 42,185 -4.19 24.64 -45,510 1,039,438
2020-01-27 2020-01-23 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 5,000 44,032 12.81
2020-01-06 2020-01-02 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 24,274 24,274 0.45 11,001 11,001
2019-10-03 2019-10-01 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 12,509 12,509 0.88 11,000 11,000
2019-07-29 2019-07-26 4 UMRX Unum Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 28,661 28,661
2019-06-14 2019-06-13 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale X -1,185 39,032 -2.95 12.10 -14,338 472,287
2019-06-14 2019-06-12 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 4,000 40,217 11.04
2019-01-28 2019-01-24 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 151,620 151,620
2019-01-28 2019-01-24 4 EPZM Epizyme, Inc.
Common Stock
A - Award 32,894 36,217 989.89
2018-02-13 2018-02-09 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 106,344 106,344
2018-02-06 2018-02-05 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
M - Exercise X -72,264 0 -100.00
2018-02-06 2018-02-05 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
S - Sale -519 2,603 -16.62 17.20 -8,927 44,772
2018-02-06 2018-02-05 4 EPZM Epizyme, Inc.
Commons Stock, par value $0.0001
S - Sale -71,745 3,122 -95.83 16.63 -1,192,768 51,904
2018-02-06 2018-02-05 4 EPZM Epizyme, Inc.
Commons Stock, par value $0.0001
M - Exercise 72,264 74,867 2,776.18 9.58 692,289 717,226
2017-03-02 2017-02-28 4 EPZM Epizyme, Inc.
Common stock, par value $0.0001
A - Award 1,708 1,708 6.21 10,613 10,613
2017-02-09 2017-02-08 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 109,866 109,866
2016-05-17 2016-05-16 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 173,438 173,438
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)